StockNews.AI
BIOA
StockNews.AI
210 days

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioAge Labs, Inc. of Class Action Lawsuit and Upcoming Deadlines - BIOA

1. A class action lawsuit is filed against BioAge Labs. 2. Allegations concern securities fraud and unlawful business practices. 3. BioAge's stock fell 76.85% after discontinuing a clinical trial. 4. Investors can join the lawsuit before March 10, 2025. 5. Pomerantz LLP is leading the class action.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit may increase investor skepticism, impacting stock performance as seen previously with similar cases.

How important is it?

Given the nature of the allegations, they can significantly impact BioAge's stock and investor sentiment.

Why Short Term?

Immediate investor response may lead to short-term price volatility, typical in legal situations.

Related Companies

BIOA
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether BioAge and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until March 10, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired BioAge securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] On or around September 26, 2024, BioAge conducted its initial public offering ("IPO"), selling 12.65 million shares of common stock priced at $18.00 per share. Then, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. On this news, BioAge's stock price fell $15.44 per share, or 76.85%, to close at $4.65 per share on December 9, 2024. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP

Related News